Friedrich Bernd, Schmidt Reinhold, Reiss Irwin, Günther Andreas, Seeger Werner, Müller Matthias, Thul Joseph, Schranz Dietmar, Gortner Ludwig
Department of Pediatrics, Justus-Leibig-University, Giessen, Germany.
Crit Care Med. 2003 Jan;31(1):284-90. doi: 10.1097/00003246-200301000-00045.
The aim of the present study was to characterize pulmonary surfactant properties in children undergoing cardiovascular surgery with cardiopulmonary bypass.
Prospective clinical trial.
University hospital pediatric intensive care unit.
Fifty pediatric patients with congenital cardiac defects undergoing cardiovascular surgery with (n = 35) and without (n = 15) cardiopulmonary bypass procedure.
Tracheal aspirates were collected by saline lavage during routine suctioning before (baseline) and after cardiopulmonary bypass, as well as 4, 8, and 24 hrs after admission to the pediatric intensive care unit.
Total protein and phospholipid concentrations were assessed in native tracheal aspirates, in large surfactant aggregates, and in small surfactant aggregates. Phospholipid profiles and phosphatidylcholine fatty acids; surfactant apoproteins SP-A, SP-B, and SP-C (enzyme-linked immunosorbent assay); and surface activity (Pulsating Bubble Surfactometer) were all analyzed in large surfactant aggregates. With cardiopulmonary bypass, an initial increase in total protein content was followed by an increase in phospholipid concentration in tracheal aspirates. Large surfactant aggregates decreased 4 hrs after cardiopulmonary bypass (4 hrs, 22.6 +/- 5.6%; mean +/- SEM; p<.01 compared with baseline, 55.4 +/- 9.2%) but recovered within 24 hrs. The phospholipid-protein ratio of large surfactant aggregates 24 hrs after cardiopulmonary bypass (1.2 +/- 0.2; p<.01) was significantly decreased compared with baseline (2.9 +/- 0.6). The relative amount of phosphatidylglycerol content in the large surfactant aggregates-fraction dropped linearly over time but other phospholipids remained mainly unchanged. Phosphatidylcholine fatty acid profiles remained unaffected by cardiopulmonary bypass. The relative content of SP-B and SP-C in large surfactant aggregates increased approximately three-fold compared with baseline. Altogether, our findings with recovered large surfactant aggregate/small surfactant aggregate ratios and increased phospholipid in tracheal aspirates after 24 hrs represent an approximately ten-fold increase in large surfactant aggregate-associated SP-B and SP-C compared with baseline. Only minor changes were detected in biophysical properties of large surfactant aggregates throughout the observation period.
Cardiopulmonary bypass procedure in children induces profound changes in the surfactant system involving both phospholipid and protein components; biophysical function may have been maintained by compensatory increase in SP-B and SP-C.
本研究旨在描述接受体外循环心脏手术的儿童的肺表面活性物质特性。
前瞻性临床试验。
大学医院儿科重症监护病房。
50例患有先天性心脏缺陷的儿科患者,其中35例接受体外循环心脏手术,15例未接受体外循环手术。
在体外循环前(基线)和体外循环后,以及入住儿科重症监护病房后4、8和24小时,通过常规吸痰时用盐水灌洗收集气管吸出物。
评估天然气管吸出物、大表面活性物质聚集体和小表面活性物质聚集体中的总蛋白和磷脂浓度。分析大表面活性物质聚集体中的磷脂谱和磷脂酰胆碱脂肪酸;表面活性物质载脂蛋白SP-A、SP-B和SP-C(酶联免疫吸附测定);以及表面活性(脉动气泡表面张力仪)。体外循环时,气管吸出物中总蛋白含量先增加,随后磷脂浓度增加。体外循环后4小时大表面活性物质聚集体减少(4小时,22.6±5.6%;平均值±标准误;与基线相比p<0.01,基线为55.4±9.2%),但在24小时内恢复。体外循环后24小时大表面活性物质聚集体的磷脂-蛋白比(1.2±0.2;p<0.01)与基线(2.9±0.6)相比显著降低。大表面活性物质聚集体部分中磷脂酰甘油含量的相对量随时间呈线性下降,但其他磷脂基本保持不变。磷脂酰胆碱脂肪酸谱不受体外循环影响。大表面活性物质聚集体中SP-B和SP-C的相对含量与基线相比增加了约三倍。总体而言,我们的研究结果显示,24小时后气管吸出物中大表面活性物质聚集体/小表面活性物质聚集体的比例恢复,磷脂增加,与基线相比,与大表面活性物质聚集体相关的SP-B和SP-C增加了约十倍。在整个观察期内,大表面活性物质聚集体的生物物理特性仅检测到轻微变化。
儿童体外循环手术可引起表面活性物质系统的深刻变化,涉及磷脂和蛋白质成分;生物物理功能可能通过SP-B和SP-C的代偿性增加得以维持。